India's Glenmark Signs Licensing Deal With Lay Line Genomics
This article was originally published in PharmAsia News
Executive Summary
India's Glenmark Pharmaceuticals has signed a licensing agreement with Lay Line Genomics of Italy to promote it's treatments for chronic pain and inflammation